Acadian Asset Management LLC Cyclacel Pharmaceuticals, Inc. Transaction History

Acadian Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.54 - $21.75 $2,219 - $89,392	-4,110 Reduced 1.12%	363,367 $240,000
Q3 2022 Nov 14, 2022	BUY	$1.23 - $21.9 $369,709 - $6.58 Million	300,577 Added 449.29%	367,477 $535,000
Q2 2022 Aug 09, 2022	BUY	$6.1 - $7.15 $403,240 - $472,650	66,105 Added 8315.09%	66,900 $72,000
Q1 2022 May 12, 2022	SELL	$5.93 - $7.6 $133,110 - $170,597	-22,447 Reduced 96.58%	795 $2,000
Q4 2021 Feb 10, 2022	BUY	$6.04 - $8.03 $140,381 - $186,633	23,242 New	23,242 $89,000
Q3 2021 Nov 12, 2021	SELL	$8.02 - $11.0 $52,146 - $71,522	-6,502 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$7.59 - $10.48 $209,142 - $288,776	-27,555 Reduced 80.91%	6,502 $38,000
Q1 2021 May 11, 2021	BUY	$6.86 - $9.24 $233,631 - $314,686	34,057 New	34,057 $242,000
Q3 2020 Nov 09, 2020	SELL	$4.81 - $6.49 $239,090 - $322,598	-49,707 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$5.2 - $7.75 $258,476 - $385,229	49,707 New	49,707 $231,000

Ticker CYCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,539,200
Market Cap $6.02M
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.